CNS Pharmaceuticals Inc., a Nevada-based corporation, has announced the entry into a placement agency agreement with A.G.P./Alliance Global Partners for a public offering. The offering includes 325,000 shares of the company's common stock and pre-funded warrants to purchase 3,627,570 shares of common stock, as well as Series F Warrants for an aggregate of 3,952,570 shares. The combined purchase price for each common stock share and accompanying warrant was set at $1.265, while the pre-funded warrant and accompanying warrant were priced at $1.264. The offering was made under a Registration Statement filed with the Securities and Exchange Commission, and the company has entered into a Securities Purchase Agreement with an institutional investor participating in the offering.